A new study at INSERM, the French National Institute of Health and Medical Research, has uncovered a new potential biomarker to predict response to chemotherapy for non-small cell lung cancer patients. One of the leading causes of cancer-related death, non-small cell lung cancer is most often treated with cisplatin, however due to cancer cell resistance, this treatment is not particularly effective. Dr. Guido Kroemer and his team are thus looking into new genes and/or proteins that offer better treatment outlook. Pyridoxal Kinase (PDXK), "an enzyme that converts vitamin B6 precursors into their active form." Non-small cell lung cancer patients with high levels of PDXK exhibited higher survival rates than those with low levels of this enzyme.
To read more about this study, click here.
Study mentioned: Galluzzi L et al. Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep. 2012 Jul 26 [Epub ahead of print]. PMID 22854025
No comments:
Post a Comment